LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

Search

Revvity Inc

Nyitva

SzektorEgészségügy

106.34 6.38

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

98.97

Maximum

106.68

Fő mutatók

By Trading Economics

Bevétel

-58M

41M

Értékesítés

-61M

711M

P/E

Szektor átlag

47.615

49.712

Egy részvényre jutó nyereség

1.06

Osztalékhozam

0.28

Profit margin

5.726

Munkavállalók

11,000

EBITDA

-38M

180M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+4.76% upside

Osztalékok

By Acuity

Osztalékhozam

Szektor átlag

0.28%

2.36%

Következő eredményjelentés

2026. júl. 27.

Következő osztalékfizetési dátum

2026. aug. 7.

Következő korábbi osztalék dátum

2026. júl. 17.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1.4B

11B

Előző nyitás

99.96

Előző zárás

106.34

Hangulat hírek alapján

By Acuity

19%

81%

36 / 342 Rangsor szerint Healthcare

Revvity Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Rólunk Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat